PDCD1 and cancer: In this regard, immune checkpoints (ICs) such as Programmed Death-1 receptor (PD-1) and its endogenous ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), have been shown to be validated targets for cancer treatments [4].